The role of levosimendan in phosphine-induced cardiotoxicity: evaluation of electrocardiographic, echocardiographic, and biochemical parameters

References

• Abdolghaffari AH, Baghaei A, Solgi R, Gooshe M, Baeeri M, Navaei-Nigjeh M, Hassani S, Jafari A, Rezayat SM, Dehpour AR, et al. 2015. Molecular and biochemical evidences on the protective effects of triiodothyronine against phosphine-induced cardiac and mitochondrial toxicity. Life Sci. 139:30–39.
   PubMed Web of Science ®Google Scholar
• Akhtar MS, Pillai KK, Hassan MQ, Dhyani N, Ismail MV, Najmi AK. 2016. Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway. Life Sci. 153:55–65.
   PubMed Web of Science ®Google Scholar
• Akhtar MS, Pillai KK, Hassan Q, Ansari SH, Ali J, Akhtar M, Najmi AK. 2016. Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy. Clin Exp Hypertens. 38(1):10–22.
   PubMed Web of Science ®Google Scholar
• Akkaoui M, Achour S, Abidi K, Himdi B, Madani A, Zeggwagh AA, Abouqal R. 2007. Reversible myocardial injury associated with aluminum phosphide poisoning. Clin Toxicol. 45(6):728–731.
   Web of Science ®Google Scholar
• Alkan M, Çelik A, Bilge M, Kiraz HA, Kip G, Özer A, Şıvgın V, Erdem Ö, Arslan M, Kavutçu M. 2015. The effect of levosimendan on lung damage after myocardial ischemia reperfusion in rats in which experimental diabetes was induced. J Surg Res. 193(2):920–925.
   PubMed Web of Science ®Google Scholar
• Aminzadeh A, Mehrzadi S. 2018. Cardioprotective effect of levosimendan against homocysteine-induced mitochondrial stress and apoptotic cell death in H9C2. Biochem Biophys Res Commun. 507(1–4):395–399.
   PubMed Web of Science ®Google Scholar
• Anand R, Binukumar B, Gill KD. 2011. Aluminum phosphide poisoning: an unsolved riddle. J Appl Toxicol. 31(6):499–505.
   PubMed Web of Science ®Google Scholar
• Anand R, Kumari P, Kaushal A, Bal A, Wani WY, Sunkaria A, Dua R, Singh S, Bhalla A, Gill KD. 2012. Effect of acute aluminum phosphide exposure on rats – a biochemical and histological correlation. Toxicol Lett. 215(1):62–69.
   PubMed Web of Science ®Google Scholar
• Asghari MH, Moloudizargari M, Baeeri M, Baghaei A, Rahimifard M, Solgi R, Jafari A, Aminjan HH, Hassani S, Moghadamnia AA, et al. 2017. On the mechanisms of melatonin in protection of aluminum phosphide cardiotoxicity. Arch Toxicol. 91(9):3109–3120.
   PubMed Web of Science ®Google Scholar
• Baeeri M, Shariatpanahi M, Baghaei A, Ghasemi-Niri SF, Mohammadi H, Mohammadirad A, Hassani S, Bayrami Z, Hosseini A, Rezayat SM, et al. 2013. On the benefit of magnetic magnesium nanocarrier in cardiovascular toxicity of aluminum phosphide. Toxicol Ind Health. 29(2):126–135.
   PubMed Web of Science ®Google Scholar
• Baghaei A, Solgi R, Jafari A, Abdolghaffari AH, Golaghaei A, Asghari MH, Baeeri M, Ostad SN, Sharifzadeh M, Abdollahi M. 2016. Molecular and biochemical evidence on the protection of cardiomyocytes from phosphine-induced oxidative stress, mitochondrial dysfunction and apoptosis by acetyl-l-carnitine. Environ Toxicol Pharmacol. 42:30–37.
   PubMed Web of Science ®Google Scholar
• Basel H, Kavak S, Demir H, Meral I, Ekim H, Bektas H. 2013. Effect of levosimendan injection on oxidative stress of rat myocardium. Toxicol Ind Health. 29(5):435–440.
   PubMed Web of Science ®Google Scholar
• Bogle R, Theron P, Brooks P, Dargan P, Redhead J. 2006. Aluminium phosphide poisoning. Emerg Med J. 23(1):e03–e03.
   PubMed Web of Science ®Google Scholar
• Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72(1–2):248–254.
   PubMed Web of Science ®Google Scholar
• Brunner SN, Bogert NV, Schnitzbauer AA, Juengel E, Moritz A, Werner I, Kornberger A, Beiras-Fernandez A. 2017. Levosimendan protects human hepatocytes from ischemia-reperfusion injury. PLoS One. 12(11):e0187839.
   PubMed Web of Science ®Google Scholar
• CDC. 2017, November 9. PHOSPHINE: Lung Damaging Agent. The National Institute for Occupational Safety and Health; [accessed 2021 Jun 30]. https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750035.html.
   Google Scholar
• Cooperstein S, Lazarow A. 1951. A microspectrophotometric method for the determination of cytochrome oxidase. J Biol Chem. 189(2):665–670.
   PubMed Web of Science ®Google Scholar
• Du Toit E, Hofmann D, McCarthy J, Pineda C. 2001. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart. 86(1):81–87.
   PubMed Web of Science ®Google Scholar
• Du Toit E, Muller C, McCarthy J, Opie L. 1999. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther. 290(2):505–514.
   PubMed Web of Science ®Google Scholar
• Efentakis P, Varela A, Chavdoula E, Sigala F, Sanoudou D, Tenta R, Gioti K, Kostomitsopoulos N, Papapetropoulos A, Tasouli A, et al. 2020. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy . Cardiovasc Res. 116(3):576–591.
   PubMed Web of Science ®Google Scholar
• Egan JR, Clarke AJ, Williams S, Cole AD, Ayer J, Jacobe S, Chard RB, Winlaw DS. 2006. Levosimendan for low cardiac output: a pediatric experience. J Intensive Care Med. 21(3):183–187.
   PubMedGoogle Scholar
• Eriksson O, Pollesello P, Haikala H. 2004. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol. 44(3):316–321.
   PubMed Web of Science ®Google Scholar
• Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbach J, Rex S, Mik EG. 2008. Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med. 36(6):1886–1891.
   PubMed Web of Science ®Google Scholar
• Gecit I, Kavak S, Yüksel MB, Basel H, Bektaş H, Gümrükçüoğlu HA, Meral I, Demir H. 2014. Effect of short-term treatment with levosimendan on oxidative stress in renal tissues of rats. Toxicol Ind Health. 30(1):47–51.
   PubMed Web of Science ®Google Scholar
• Grossini E, Caimmi PP, Platini F, Molinari C, Uberti F, Cattaneo M, Valente G, Mary DA, Vacca G, Tessitore L. 2010. Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs. Cardiovasc Drugs Ther. 24(1):5–15.
   PubMed Web of Science ®Google Scholar
• Grossini E, Farruggio S, Pierelli D, Bolzani V, Rossi L, Pollesello P, Monaco C. 2020. Levosimendan improves oxidative balance in cardiogenic shock/low cardiac output patients. J Clin Med. 9(2):373.
   PubMed Web of Science ®Google Scholar
• Gupta M, Malik A, Sharma V. 1995. Cardiovascular manifestations in aluminium phosphide poisoning with special reference to echocardiographic changes. J Assoc Physicians India. 43(11):773–774.
   PubMedGoogle Scholar
• Haghi-Aminjan H, Baeeri M, Rahimifard M, Alizadeh A, Hodjat M, Hassani S, Asghari MH, Abdollahi A, Didari T, Hosseini R, et al. 2018. The role of minocycline in alleviating aluminum phosphide-induced cardiac hemodynamic and renal toxicity. Environ Toxicol Pharmacol. 64:26–40.
   PubMed Web of Science ®Google Scholar
• Haghi Aminjan H, Abtahi SR, Hazrati E, Chamanara M, Jalili M, Paknejad B. 2019. Targeting of oxidative stress and inflammation through ROS/NF-kappaB pathway in phosphine-induced hepatotoxicity mitigation. Life Sci. 232:116607.
   PubMed Web of Science ®Google Scholar
• Hajjej Z, Meddeb B, Sellami W, Labbene I, Morelli A, Ferjani M. 2017. Effects of levosimendan on cellular metabolic alterations in patients with septic shock: a randomized controlled pilot study. Shock. 48(3):307–312.
   PubMed Web of Science ®Google Scholar
• Hosseini A, Abdollahi M, Hassanzadeh G, Rezayat M, Hassani S, Pourkhalili N, Tabrizian K, Khorshidahmad T, Beyer C, Sharifzadeh M. 2011. Protective effect of magnesium-25 carrying porphyrin-fullerene nanoparticles on degeneration of dorsal root ganglion neurons and motor function in experimental diabetic neuropathy. Basic Clin Pharmacol Toxicol. 109(5):381–386.
   PubMed Web of Science ®Google Scholar
• Jafari A, Baghaei A, Solgi R, Baeeri M, Chamanara M, Hassani S, Gholami M, Ostad SN, Sharifzadeh M, Abdollahi M. 2015. An electrocardiographic, molecular and biochemical approach to explore the cardioprotective effect of vasopressin and milrinone against phosphide toxicity in rats. Food Chem Toxicol. 80:182–192.
   PubMed Web of Science ®Google Scholar
• Kandemir U, Maltepe F, Ugurlu B, Gokmen N, Celik A. 2013. The effects of levosimendan and dobutamine in experimental bupivacaine-induced cardiotoxicity. BMC Anesthesiol. 13(1):28.
   PubMedGoogle Scholar
• Karami-Mohajeri S, Jafari A, Abdollahi M. 2013. Comprehensive review of the mechanistic approach and related therapies to cardiovascular effects of aluminum phosphide. Int J Pharmacol. 9(8):493–500.
   Google Scholar
• Kiraz HA, Poyraz F, Kip G, Erdem Ö, Alkan M, Arslan M, Özer A, Şivgin V, Çomu FM. 2015. The effect of levosimendan on myocardial ischemia–reperfusion injury in streptozotocin-induced diabetic rats. Libyan J Med. 10(1):29269.
   PubMedGoogle Scholar
• Lall S, Peshin S, Mitra S. 2000. Methemoglobinemia in aluminium phosphide poisoning in rats. Indian J Exp Biol. 38(1):95–97.
   PubMedGoogle Scholar
• Leppikangas H, Ruokonen E, Rutanen J, Kiviniemi V, Lindgren L, Kurola J. 2009. Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study. Ann Emerg Med. 54(6):811–817.e813.
   PubMed Web of Science ®Google Scholar
• Li L-L, Wei L, Zhang N, Wei W-Y, Hu C, Deng W, Tang Q-Z. 2020. Levosimendan protects against doxorubicin-induced cardiotoxicity by regulating the PTEN/Akt pathway. Biomed Res Int. 2020:8593617.
   PubMed Web of Science ®Google Scholar
• Lilleberg J, Ylönen V, Lehtonen L, Toivonen L. 2004. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J. 38(2):80–84.
   PubMed Web of Science ®Google Scholar
• Markou T, Makridou Z, Galatou E, Lazou A. 2011. Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes. Eur J Pharmacol. 667(1–3):298–305.
   PubMed Web of Science ®Google Scholar
• Maytin M, Colucci WS. 2005. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol. 96(6):26–31.
   Google Scholar
• Mehrpour O, Jafarzadeh M, Abdollahi M. 2012. A systematic review of aluminium phosphide poisoning. Arh Hig Rada Toksikol. 63(1):61–73.
   PubMed Web of Science ®Google Scholar
• Moeini-Nodeh S, Rahimifard M, Baeeri M, Abdollahi M. 2017. Functional improvement in rats’ pancreatic islets using magnesium oxide nanoparticles through antiapoptotic and antioxidant pathways. Biol Trace Elem Res. 175(1):146–155.
   PubMed Web of Science ®Google Scholar
• Moghadamnia AA. 2012. An update on toxicology of aluminum phosphide. Daru. 20(1):25.
   PubMedGoogle Scholar
• Mohan B, Singh B, Gupta V, Ralhan S, Gupta D, Puri S, Goyal A, Aslam N, Tandon R, Wander GS. 2016. Outcome of patients supported by extracorporeal membrane oxygenation for aluminum phosphide poisoning: an observational study. Indian Heart J. 68(3):295–301.
   PubMedGoogle Scholar
• Momtaz S, Baeeri M, Rahimifard M, Haghi-Aminjan H, Hassani S, Abdollahi M. 2019. Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells. J Cell Biochem. 120(4):6209–6222.
   PubMed Web of Science ®Google Scholar
• Najafi M, Hooshangi Shayesteh MR, Mortezaee K, Farhood B, Haghi-Aminjan H. 2020. The role of melatonin on doxorubicin-induced cardiotoxicity: a systematic review. Life Sci. 241:117173.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Pollesello P, Vajda G, Papp Z. 2009. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 53(4):302–310.
   PubMed Web of Science ®Google Scholar
• Nobakht-Haghighi N, Rahimifard M, Baeeri M, Rezvanfar MA, Moini Nodeh S, Haghi-Aminjan H, Hamurtekin E, Abdollahi M. 2018. Regulation of aging and oxidative stress pathways in aged pancreatic islets using alpha-lipoic acid. Mol Cell Biochem. 449(1-2):267–276. eng.
   PubMed Web of Science ®Google Scholar
• Papp JG, Pollesello P, Varró AF, Végh ÁS. 2006. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther. 11(2):129–135.
   PubMed Web of Science ®Google Scholar
• Paraskevaidis IA, Parissis JT, Th Kremastinos D. 2005. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents. 3(3):243–247.
   PubMedGoogle Scholar
• Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT. 2008. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs. 17(8):1143–1150.
   PubMed Web of Science ®Google Scholar
• Pataricza J, Krassói I, Höhn J, Kun A, Papp JG. 2003. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther. 17(2):115–121.
   PubMed Web of Science ®Google Scholar
• Rahimifard M, Baeeri M, Bahadar H, Moini-Nodeh S, Khalid M, Haghi-Aminjan H, Mohammadian H, Abdollahi M. 2020. Therapeutic effects of gallic acid in regulating senescence and diabetes; an in vitro study. Molecules. 25(24):5875.
   Web of Science ®Google Scholar
• Rogatzki MJ, Ferguson BS, Goodwin ML, Gladden LB. 2015. Lactate is always the end product of glycolysis. Front Neurosci. 9:22.
   PubMed Web of Science ®Google Scholar
• Schlüter KD, Schreiber D. 2005. Adult ventricular cardiomyocytes: isolation and culture. Methods Mol Biol. 290:305–314.
   PubMedGoogle Scholar
• Scoote M, Williams AJ. 2004. Myocardial calcium signalling and arrhythmia pathogenesis. Biochem Biophys Res Commun. 322(4):1286–1309.
   PubMed Web of Science ®Google Scholar
• Shadnia S, Rahimi M, Pajoumand A, Rasouli M-H, Abdollahi M. 2005. Successful treatment of acute aluminium phosphide poisoning: possible benefit of coconut oil. Hum Exp Toxicol. 24(4):215–218.
   PubMed Web of Science ®Google Scholar
• Shadnia S, Soltaninejad K, Hassan Ian-Moghadam H, Sadeghi A, Rahimzadeh H, Zamani N, Ghasemi-Toussi A, Abdollahi M. 2011. Methemoglobinemia in aluminum phosphide poisoning. Hum Exp Toxicol. 30(3):250–253.
   PubMed Web of Science ®Google Scholar
• Shah V, Baxi S, Vyas T. 2009. Severe myocardial depression in a patient with aluminium phosphide poisoning: a clinical, electrocardiographical and histopathological correlation. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of. Indian J Crit Care Med. 13(1):41–43.
   PubMedGoogle Scholar
• Sherwood S, Hirst J. 2006. Investigation of the mechanism of proton translocation by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria: does the enzyme operate by a Q-cycle mechanism? Biochem J. 400(3):541–550.
   PubMedGoogle Scholar
• Solgi R, Baghaei A, Golaghaei A, Hasani S, Baeeri M, Navaei M, Ostad SN, Hosseini R, Abdollahi M. 2015. Electrophysiological and molecular mechanisms of protection by iron sucrose against phosphine-induced cardiotoxicity: a time course study. Toxicol Mech Methods. 25(4):249–257.
   PubMed Web of Science ®Google Scholar
• Tompkins AJ, Burwell LS, Digerness SB, Zaragoza C, Holman WL, Brookes PS. 2006. Mitochondrial dysfunction in cardiac ischemia–reperfusion injury: ROS from complex I, without inhibition. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis. 1762(2):223–231.
   PubMed Web of Science ®Google Scholar
• Torraco A, Carrozzo R, Piemonte F, Pastore A, Tozzi G, Verrigni D, Assenza M, Orecchioni A, D'Egidio A, Marraffa E, et al. 2014. Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial. Biochimie. 102:166–173.
   PubMed Web of Science ®Google Scholar
• Tsao C-M, Li K-Y, Chen S-J, Ka S-M, Liaw W-J, Huang H-C, Wu C-C. 2014. Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model. Crit Care. 18(6):652.
   PubMed Web of Science ®Google Scholar
• Uberti F, Caimmi PP, Molinari C, Mary D, Vacca G, Grossini E. 2011. Levosimendan modulates programmed forms of cell death through KATP channels and nitric oxide. J Cardiovasc Pharmacol. 57(2):246–258.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Suzuki T, Iguchi K, Sakamoto T, Tomita K, Yokoo H, Sakai M, Misawa H, Hattori K, Nagata T, et al. 2018. Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis. Naunyn Schmiedebergs Arch Pharmacol. 391(9):1021–1032.
   PubMed Web of Science ®Google Scholar
• Zangrillo A, Biondi-Zoccai G, Mizzi A, Bruno G, Bignami E, Gerli C, De Santis V, Tritapepe L, Landoni G. 2009. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 23(4):474–478.
   PubMed Web of Science ®Google Scholar
• Zhao RZ, Jiang S, Zhang L, Yu ZB. 2019. Mitochondrial electron transport chain, ROS generation and uncoupling . Int J Mol Med. 44(1):3–15.
   PubMed Web of Science ®Google Scholar